Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Opioid Use Disorder in the Elderly

  • Geriatric Disorders (M Sajatovic and A Aftab, Section Editors)
  • Published:
Current Treatment Options in Psychiatry Aims and scope Submit manuscript

Abstract

Purpose of Review

With the increasing age of those born between 1946 and 1965, issues relating to the “baby boomer” generation are more relevant than ever. This review aims to both highlight the importance of screening for substance use disorders in the elderly (specifically in this case, opioid use disorder) and then summarize the available treatment options for this vulnerable population.

Recent Findings

A narrative review of the literature showed surprisingly little research on the treatment of substance use disorders, especially opioid use disorder, in the elderly. None of the three medications that are FDA approved for opioid use disorder in adults (methadone, buprenorphine, and naltrexone) is contraindicated in the elderly. All medications should be used cautiously, keeping in mind that the elderly often have more medical issues (which can include chronic pain) as well as are on multiple medications that can lead to medication interactions.

Summary

Because there is very limited data on treatment of opioid use disorder in later life, current treatment generally follows recommendations for the general/mixed age population. More research into the topic is needed, especially with a larger percentage of the “baby boomer” generation entering the 65+ age range.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the US opioid crisis: rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018;193:142–7.

    PubMed  PubMed Central  Google Scholar 

  2. Carew AM, Comiskey C. Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend. 2018;182:48–57.

    PubMed  Google Scholar 

  3. Mattson M, Lipari RN, Hays C, Van Horn SL (2017) A day in the life of older adults: substance use facts. InThe CBHSQ Report. Substance Abuse and Mental Health Services Administration (US)

  4. Levi-Minzi MA, Surratt HL, Kurtz SP, Buttram ME. Under treatment of pain: a prescription for opioid misuse among the elderly? Pain Med. 2013;14(11):1719–29.

    PubMed  Google Scholar 

  5. Bhatia U, Nadkarni A, Murthy P, Rao R, Crome I. Recent advances in treatment for older people with substance use problems: an updated systematic and narrative review. Eur Geriatr Med. 2015;6(6):580–6.

    Google Scholar 

  6. Le Roux C, Tang Y, Drexler K. Alcohol and opioid use disorder in older adults: neglected and treatable illnesses. Curr Psychiatry Rep. 2016;18(9):87.

    PubMed  Google Scholar 

  7. Center for Substance Abuse Treatment (1998) Substance abuse among older adults: Tip 26

  8. Butler RN. Age-ism: another form of bigotry. The Gerontologist. 1969;9(4_Part_1):243–6.

    CAS  PubMed  Google Scholar 

  9. Kaiser Family Foundation analysis of Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death 1999–2018 on CDC WONDER Online Database, released 2020

  10. Abuse S, Administration MH (2018) National survey on drug use and health

  11. Joshi P, Shah NK, Kirane HD. Medication-assisted treatment for opioid use disorder in older adults: an emerging role for the geriatric psychiatrist. Am J Geriatr Psychiatry. 2019;27(4):455–7.

    PubMed  Google Scholar 

  12. Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of older opioid maintenance patients. J Subst Abus Treat. 2005;28(3):265–72.

    Google Scholar 

  13. Kumar R, Viswanath O, Saadabadi A. Buprenorphine. [Updated 2020 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459126/

  14. Velander JR. Suboxone: rationale, science, misconceptions. Ochsner J. 2018;18(1):23–9.

    PubMed  PubMed Central  Google Scholar 

  15. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N (2016) Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. (5)

  16. Suboxone [package insert on the internet] Accessed March 2, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022410s000lbl.pdf

  17. Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity. J Med Toxicol. 2018;14(4):306–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Gorman AL, Elliott KJ, Inturrisi CE. The d-and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223(1):5–8.

    CAS  PubMed  Google Scholar 

  19. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14(11):747–53.

    CAS  PubMed  Google Scholar 

  20. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501–4.

    CAS  PubMed  Google Scholar 

  21. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, et al. Influence of opioid agonists on cardiac humanether-a-go-go-related gene K+ currents. J Pharmacol Exp Ther. 2002;303(2):688–94.

    CAS  PubMed  Google Scholar 

  22. Isbister GK, Brown AL, Gill A, Scott AJ, Calver L, Dunlop AJ. QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings. Br J Clin Pharmacol. 2017;83(10):2274–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9.

    PubMed  Google Scholar 

  24. Moryl N, Pope J, Obbens E. Hypoglycemia during rapid methadone dose escalation. J Opioid Manag. 2013;9(1):29–34.

    PubMed  Google Scholar 

  25. Salsitz E, Wiegand T Pharmacotherapy of opioid addiction: “Putting a real face on a false demon”. In Journal of Medical Toxicology 2016 Mar 1 (Vol. 12, No. 1, pp. 58–63). Springer US

  26. Symonds P. Methadone and the elderly. Br Med J. 1977;1(6059):512.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Pascarelli EF, Fischer W. Drug dependence in the elderly. Int J Aging Hum Dev. 1974;5(4):347–56.

    CAS  PubMed  Google Scholar 

  28. Pascarelli EF. An update on drug dependence in the elderly. J Drug Issues. 1979;9(1):47–54.

    Google Scholar 

  29. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.

    PubMed  Google Scholar 

  30. Guo S, Winslow M, Manning V, Thane KK. Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore. Ann Acad Med Singap. 2010;39(6):429.

    PubMed  Google Scholar 

  31. Rajaratnam R, Sivesind D, Todman M, Roane D, Seewald R. The aging methadone maintenance patient: treatment adjustment, long-term success, and quality of life. J Opioid Manag. 2009;5(1):27–37.

    PubMed  Google Scholar 

  32. Fareed A, Casarella J, Amar R, Drexler K. Dose-dependent cognitive impairment in an elder methadone-maintained patient. J Addict Med. 2009;3(2):109–10.

    PubMed  Google Scholar 

  33. Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. Drug Alcohol Depend. 2005;78(2):225–30.

    CAS  PubMed  Google Scholar 

  34. Y Wang G, A Wouldes T, R Russell B. Methadone maintenance treatment and cognitive function: a systematic review. Curr Drug Abuse Rev. 2013;6(3):220–30.

    Google Scholar 

  35. Oesterle TS, Thusius NJ, Rummans TA, Gold MS (2019) Medication-assisted treatment for opioid-use disorder. In Mayo Clinic Proceedings. Elsevier.

  36. Marrazzi MA, Wroblewski JM, Kinzie J, Luby ED. High-dose naltrexone and liver function safety. Am J Addict. 1997;6(1):21–9.

    CAS  PubMed  Google Scholar 

  37. Ayanga D, Shorter D, Kosten TR. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother. 2016;17(17):2307–18.

    CAS  PubMed  Google Scholar 

  38. Kleber HD. Naltrexone. J Subst Abus Treat. 1985;2(2):117–22.

    CAS  Google Scholar 

  39. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2011) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev (4)

  40. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13.

    CAS  PubMed  Google Scholar 

  41. Lal R, Pattanayak RD. Alcohol use among the elderly: issues and considerations. J Geriatr Ment Health. 2017;4(1):4.

    Google Scholar 

  42. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Tetrault JM, Moore BA, Barry DT, O’Connor PG, Schottenfeld R, Fiellin DA, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abus Treat. 2012;43(4):433–9.

    Google Scholar 

  44. Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788–98.

    PubMed  Google Scholar 

  45. Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O’Connor PG, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74–e11.

    PubMed  PubMed Central  Google Scholar 

  46. Moore BA, Fiellin DA, Cutter CJ, Buono FD, Barry DT, Fiellin LE, et al. Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. J Subst Abus Treat. 2016;71:54–7.

    Google Scholar 

  47. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol. 1997;65(5):803.

    CAS  PubMed  Google Scholar 

  48. Pan S, Jiang H, Du J, Chen H, Li Z, Ling W, et al. Efficacy of cognitive behavioral therapy on opiate use and retention in methadone maintenance treatment in China: a randomised trial. PLoS One. 2015;10(6).

  49. Barry DT, Beitel M, Cutter CJ, Fiellin DA, Kerns RD, Moore BA, et al. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain. Drug Alcohol Depend. 2019;194:460–7.

    PubMed  Google Scholar 

  50. Kelly JF, Greene MC, Bergman BG. Do drug-dependent patients attending alcoholics anonymous rather than narcotics anonymous do as well? A prospective, lagged, matching analysis. Alcohol Alcohol. 2014;49(6):645–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Substance Abuse and Mental Health Services Administration. Addressing the specific behavioral health needs of men. Treatment Improvement Protocol (TIP) Series 56. HHS Publication No.(SMA) 13–4736. 2013:1–245.

  52. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone. J Subst Abus Treat. 2018;85:49–55.

    Google Scholar 

  53. Moyo P. Opioid use disorder and its treatment among older adults: an invited commentary. Am J Geriatr Psychiatry. 2019;27(4):346–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James J Peters Bronx VA Hospital, Icahn School of Medicine at Mount Sinai, 513 West 142nd St, Unit 2, New York, NY, 10031, USA

    Christine LaGrotta

Authors
  1. Christine LaGrotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine LaGrotta.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Geriatric Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

LaGrotta, C. Treatment of Opioid Use Disorder in the Elderly. Curr Treat Options Psych 7, 531–543 (2020). https://doi.org/10.1007/s40501-020-00231-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40501-020-00231-x

Keywords

Search

Navigation